
Study Identifies First Structure of C. diff Toxin B, Paving the Way for Next Generation Therapeutics
Investigators found that the therapeutic mechanism for bezlotoxumab, the only FDA-approved anti-TcdB antibody, is sensitive to escaping mutations in some bacterial strains.



































